-
DDRGK1 UFMylation Controls STAT3 in Osteoarthritis
2026-09-14
The reference study identifies DDRGK1-mediated UFMylation as a regulatory brake on STAT3 phosphorylation, nuclear translocation, and inflammatory cartilage degeneration. By combining human cartilage analysis, conditional mouse genetics, multi-omics, protein-interaction assays, and pharmacological rescue, the authors connect loss of DDRGK1 activity with osteoarthritis progression and nominate STAT3 inhibition as a mechanistically supported intervention.
-
Fulvestrant: ERα Degradation for Causal Assays
2026-09-13
Fulvestrant (ICI 182,780) is more than an estrogen antagonist: it is a pharmacological tool for separating ERα signaling, MDM2 protein degradation, and chemotherapy response. This article translates receptor-selective evidence into practical assay decisions while defining the limits of cross-domain interpretation.
-
SEMA3E, β-Catenin, and Beige Fat Thermogenesis
2026-09-12
A 2026 study identifies SEMA3E as a positive regulator of beige adipocyte differentiation and non-shivering thermogenesis in mice, linking its activity to mitochondrial respiration and Wnt/β-catenin signaling. The work combines adipose-tissue perturbation, transplantation, transcriptomics, and metabolic assays to define a mechanistic framework for studying thermogenic fat biology.
-
Dorsomorphin 2HCl: AMPK Inhibitor Guide
2026-09-11
Dorsomorphin 2HCl is a preclinical AMPK inhibitor that also suppresses BMP receptor signaling. Its dual activity supports mechanistic studies of hepatic lipid metabolism, osteogenic differentiation, hepcidin expression regulation, and iron homeostasis research.
-
IBDV VP3 Disrupts IRF7 to Promote Viral Replication
2026-09-11
A 2025 Frontiers study identifies IBDV VP3 as an antagonist of chicken IRF7-mediated type I interferon signaling. Using infection, gene perturbation, proteasome inhibition, and protein-interaction analyses, the authors show that VP3 promotes IRF7 degradation and thereby supports viral replication.
-
Estradiol, ER Signaling, and T-Cell Recovery After Shock
2026-09-10
This study identifies endoplasmic reticulum stress as a mechanistic link between hemorrhagic shock and impaired splenic CD4+ T-lymphocyte function. Pharmacological evidence indicates that estradiol restores T-cell proliferation and cytokine production mainly through ERα and GPR30-associated signaling, rather than ERβ, by reducing stress responses.
-
20-HETE–TRPV1 Signaling in Chronic Dermatitis
2026-09-10
The reference study identifies a peripheral mechanism by which elevated 20-HETE activates TRPV1 on sensitized MrgprA3+ sensory neurons and converts normally painful stimulation into itch-related allokinesis in chronic dermatitis. Its combination of behavioral, neuronal, metabolomic, and pharmacological experiments supports 20-HETE–TRPV1–MrgprA3 signaling as a mechanistic target for chronic itch research.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-09-09
This study develops a localized, nonviral strategy for bladder cancer by delivering chemically modified CDKN1A/p21 mRNA in lipid nanoparticles through intravesical administration. The findings connect transient nuclear p21 restoration with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced orthotopic tumor growth while limiting systemic exposure.
-
Abiraterone Acetate in 3D Prostate Cancer Models
2026-09-09
A translational framework for using Abiraterone acetate as a CYP17 inhibitor in patient-derived prostate cancer spheroids, with emphasis on mechanism, exposure control, model limitations, and strategic assay design.
-
Fulvestrant (ICI 182,780) Research Workflows
2026-09-08
Build reproducible ER-signaling, MDM2 degradation, apoptosis, and chemotherapy-sensitization assays with Fulvestrant (ICI 182,780). This guide connects breast cancer workflows with carefully bounded lessons from an estrogen-dependent immune-recovery study.
-
Rocilinostat (ACY-1215) HDAC6 Workflow Guide
2026-09-08
Rocilinostat (ACY-1215) enables selective HDAC6 perturbation for multiple myeloma viability, apoptosis, and proteasome-inhibitor combination studies. This guide pairs target-engagement controls with practical dosing, cilia-aware assay design, and troubleshooting strategies for reproducible preclinical experiments.
-
Dutasteride Workflows for Prostate Research
2026-09-07
Dutasteride enables controlled interrogation of testosterone-to-DHT signaling in prostate cancer and benign prostatic hyperplasia models. This practical guide combines formulation, cell-based assay design, apoptosis readouts, and cross-domain lessons from hepatocyte–macrophage research without overstating what the evidence supports.
-
Silybin A: Silymarin Assay Workflows
2026-09-07
Silybin A enables cleaner mechanistic studies than an unfractionated Silymarin mixture by providing a defined flavonolignan input. This guide covers DMSO stock preparation, hepatocyte and inflammation workflows, stereochemical controls, and troubleshooting for oxidative stress reduction and liver disease research.
-
GSK126: Practical EZH2 Inhibitor Workflows
2026-09-05
GSK126 provides a selective way to connect EZH2/PRC2 activity with H3K27me3 loss, gene reactivation, and cancer-cell phenotypes. This guide translates that mechanism into dose-response, chromatin, stem-cell, combination-treatment, and troubleshooting workflows for cancer epigenetics research and oncology drug development.
-
Prochlorperazine-Induced Neuroleptic Malignant Syndrome
2026-09-04
This case report highlights neuroleptic malignant syndrome (NMS) after standard-dose Prochlorperazine in an older adult, despite initially unremarkable or only borderline laboratory findings. Its principal contribution is a clinically grounded diagnostic and treatment framework emphasizing medication history, neurological examination, and early benzodiazepine- and amantadine-based management.